RNAi therapeutics developer Sirnaomics Inc. closed the second tranche of a $47 million series C financing with a $22 million investment led by CR-CP Life Sciences Fund, a Hong Kong-based joint venture established by China Resources Group and Charoen Pokphand Group in January. Proceeds from the round will support advancement of Sirnaomics' lead candidate, a siRNA-inhibiting polymeric nanoparticle therapy it is evaluating for the treatment of non-melanoma skin cancer (NMSC), cholangiocarcinoma and hepatocellular carcinoma.